

# Eapm Working Group For Oncology Clin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5645585/publications.pdf>

Version: 2024-02-01

61  
papers

5,025  
citations

236912

25  
h-index

168376

53  
g-index

62  
all docs

62  
docs citations

62  
times ranked

8571  
citing authors

#	ARTICLE	IF	CITATIONS
1	Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 674-690.	27.6	1,938
2	Treatment landscape of triple-negative breast cancer – expanded options, evolving needs. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 91-113.	27.6	414
3	The immune system and response to HER2-targeted treatment in breast cancer. <i>Lancet Oncology</i> , The, 2014, 15, e58-e68.	10.7	244
4	Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2011, 103, 264-272.	6.3	203
5	Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor–Positive and –Negative Cancers. <i>Journal of Clinical Oncology</i> , 2010, 28, 4316-4323.	1.6	193
6	Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study. <i>Clinical Cancer Research</i> , 2014, 20, 511-521.	7.0	191
7	Recombinant Human Erythropoietin Antagonizes Trastuzumab Treatment of Breast Cancer Cells via Jak2-Mediated Src Activation and PTEN Inactivation. <i>Cancer Cell</i> , 2010, 18, 423-435.	16.8	129
8	Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 1707.	7.1	129
9	Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients. <i>Cancer Science</i> , 2016, 107, 1730-1735.	3.9	125
10	New Strategies in Breast Cancer: Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 2105-2110.	7.0	124
11	Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer. <i>Cancer Research</i> , 2017, 77, 3317-3324.	0.9	117
12	Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma. <i>Cancer Discovery</i> , 2015, 5, 972-987.	9.4	97
13	Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. <i>Cancer Research</i> , 2020, 80, GS3-04-GS3-04.	0.9	90
14	Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor–positive, HER2–normal, grade II, lymph node–negative breast cancers. <i>Cancer</i> , 2010, 116, 5161-5167.	4.1	87
15	Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer. <i>Breast Cancer Research</i> , 2017, 19, 16.	5.0	83
16	Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer. <i>Cancer Research</i> , 2017, 77, 3280-3292.	0.9	76
17	DNA Repair Gene Patterns as Prognostic and Predictive Factors in Molecular Breast Cancer Subtypes. <i>Oncologist</i> , 2013, 18, 1063-1073.	3.7	75
18	Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 785-795.	2.5	68

#	ARTICLE	IF	CITATIONS
19	Immunotherapy for early triple negative breast cancer: research agenda for the next decade. <i>Npj Breast Cancer</i> , 2022, 8, 23.	5.2	67
20	<i>TP53</i> mutation-correlated genes predict the risk of tumor relapse and identify <i>MPS1</i> as a potential therapeutic kinase in <i>TP53</i> -mutated breast cancers. <i>Molecular Oncology</i> , 2014, 8, 508-519.	4.6	59
21	Prognostic and Therapeutic Implications of Distinct Kinase Expression Patterns in Different Subtypes of Breast Cancer. <i>Cancer Research</i> , 2010, 70, 8852-8862.	0.9	58
22	Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 337-345.	7.0	58
23	Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers. <i>Clinical Cancer Research</i> , 2011, 17, 2591-2601.	7.0	52
24	Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers. <i>Breast Cancer Research</i> , 2013, 15, R86.	5.0	44
25	First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 155-164.	2.5	36
26	Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 39-47.	2.5	28
27	Personalized Risk-Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak. <i>Oncologist</i> , 2020, 25, e1013-e1020.	3.7	28
28	Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives. <i>Cancers</i> , 2022, 14, 2136.	3.7	21
29	Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review. <i>Cancers</i> , 2022, 14, 1898.	3.7	20
30	Bax Expression Is Predictive of Favorable Clinical Outcome in Chemonaive Advanced Gastric Cancer Patients Treated with Capecitabine, Oxaliplatin, and Irinotecan Regimen. <i>Translational Oncology</i> , 2012, 5, 155-159.	3.7	19
31	OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer. <i>Molecular Oncology</i> , 2014, 8, 1196-1207.	4.6	17
32	Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 1.	5.2	17
33	Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care. <i>Public Health Genomics</i> , 2015, 18, 349-358.	1.0	14
34	Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5096-5108.	7.0	12
35	Use of Formalin-Fixed Paraffin-Embedded Samples for Gene Expression Studies in Breast Cancer Patients. <i>PLoS ONE</i> , 2015, 10, e0123194.	2.5	11
36	Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost: Should the indications for radiotherapy be more personalized?. <i>Breast</i> , 2021, 55, 45-54.	2.2	10

#	ARTICLE	IF	CITATIONS
37	Accurate Data Processing Improves the Reliability of Affymetrix Gene Expression Profiles from FFPE Samples. <i>PLoS ONE</i> , 2014, 9, e86511.	2.5	10
38	Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel. <i>Cancers</i> , 2022, 14, 1022.	3.7	10
39	Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1000-1000.	1.6	9
40	Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor <sup>+</sup> and ErbB2-positive Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2167-2179.	7.0	8
41	Gemcitabine-induced Thrombocytosis as a Potential Predictive Factor in Non-small Cell Lung Cancer: Analysis of 318 Patients. <i>Tumori</i> , 2017, 103, 143-147.	1.1	5
42	Abstract GS3-07: Circulating tumor DNA (ctDNA) dynamics in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first line with ribociclib (R) and letrozole (L) in the BioltaLEE trial. <i>Cancer Research</i> , 2022, 82, GS3-07-GS3-07.	0.9	5
43	Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 223-234.	2.5	3
44	Modulation by treatment of tumor infiltrating lymphocytes (TILs) and PDL1 expression in triple-negative breast cancer in the ETNA trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 555-555.	1.6	3
45	The TRAR gene classifier to predict response to neoadjuvant therapy in HER2 <sup>+</sup> and ER <sup>+</sup> positive breast cancer patients: an explorative analysis from the NeoSphere trial. <i>Molecular Oncology</i> , 2022, 16, 2355-2366.	4.6	3
46	Circulating tumor DNA (ctDNA) and serum thymidine kinase 1 activity (TKa) matched dynamics in patients (pts) with hormone receptor <sup>+</sup> positive (HR+), human epidermal growth factor 2 <sup>-</sup> negative (HER2-) advanced breast cancer (ABC) treated in first-line (1L) with ribociclib (RIB) and letrozole (LET) in the BioltaLEE trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1012-1012.	1.6	3
47	Surrogate Markers for Targeted Therapy-Based Treatment Activity and Efficacy. <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 91-94.	2.1	2
48	Residual disease after HER2-directed therapies in the neosphere study: Modulation of tumor lymphocyte infiltration (TIL) and prognosis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 517-517.	1.6	2
49	Proliferation-, estrogen-, and T-cell-related metagenes to predict outcome after adjuvant/neoadjuvant chemotherapy for operable breast cancer in the ECTO trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1014-1014.	1.6	2
50	Primary Founder Mutations in the PRKDC Gene Increase Tumor Mutation Load in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 633.	4.1	2
51	Breast Cancer Genomics: Challenges in Interpretation and Application. <i>Oncologist</i> , 2013, 18, e11-2.	3.7	1
52	HER2-Directed T-Cell Receptor <sup>+</sup> Mimicking Antibody: A <sup>+</sup> Me Too <sup>+</sup> or an Example of Novel Antitumor Aggressive Mimicry?. <i>Journal of the National Cancer Institute</i> , 2013, 105, 161-163.	6.3	1
53	Is trastuzumab as a single agent obsolete in early breast cancer? No. <i>Breast</i> , 2019, 43, 142-145.	2.2	1
54	Dermatological and Dermoscopic Baselines in BRCA Mutation Carriers. <i>Frontiers in Medicine</i> , 2022, 9, 863468.	2.6	1

#	ARTICLE	IF	CITATIONS
55	Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility. Journal of the National Cancer Institute Monographs, 2015, 2015, 1-3.	2.1	0
56	Dissecting Time- from Tumor-Related Gene Expression Variability in Bilateral Breast Cancer. International Journal of Molecular Sciences, 2018, 19, 196.	4.1	0
57	An immune-related signature for prediction of risk of late recurrences beyond proliferation and ER-related genes in ER-positive breast cancer.. Journal of Clinical Oncology, 2014, 32, 530-530.	1.6	0
58	Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients.. Journal of Clinical Oncology, 2015, 33, 11021-11021.	1.6	0
59	Low tumor-infiltrating lymphocytes (TILs) to predict and refine risk in patients not achieving a pathological complete response (pCR) in HER2-positive breast cancers.. Journal of Clinical Oncology, 2015, 33, e11612-e11612.	1.6	0
60	Association between DNA level aberrations and immune cell infiltration in breast cancer.. Journal of Clinical Oncology, 2016, 34, 3078-3078.	1.6	0
61	Demethylating agents to upregulate HLAs and antigen presenting machinery (APM) related genes in HER2+ breast cancer (BC) cell lines.. Journal of Clinical Oncology, 2018, 36, e13012-e13012.	1.6	0